JP2016534092A5 - - Google Patents

Download PDF

Info

Publication number
JP2016534092A5
JP2016534092A5 JP2016529755A JP2016529755A JP2016534092A5 JP 2016534092 A5 JP2016534092 A5 JP 2016534092A5 JP 2016529755 A JP2016529755 A JP 2016529755A JP 2016529755 A JP2016529755 A JP 2016529755A JP 2016534092 A5 JP2016534092 A5 JP 2016534092A5
Authority
JP
Japan
Prior art keywords
cancer
antibody
antigen
cl2a
reaction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016529755A
Other languages
English (en)
Japanese (ja)
Other versions
JP6427789B2 (ja
JP2016534092A (ja
Filing date
Publication date
Priority claimed from US13/948,732 external-priority patent/US9028833B2/en
Application filed filed Critical
Priority claimed from PCT/US2014/034518 external-priority patent/WO2015012904A2/en
Publication of JP2016534092A publication Critical patent/JP2016534092A/ja
Publication of JP2016534092A5 publication Critical patent/JP2016534092A5/ja
Application granted granted Critical
Publication of JP6427789B2 publication Critical patent/JP6427789B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016529755A 2013-07-23 2014-04-17 Cl2aリンカーを有する抗体−sn−38免疫複合体 Active JP6427789B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13/948,732 US9028833B2 (en) 2012-12-13 2013-07-23 Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity
US13/948,732 2013-07-23
PCT/US2014/034518 WO2015012904A2 (en) 2012-12-13 2014-04-17 Antibody-sn-38 immunoconjugates with a cl2a linker

Publications (3)

Publication Number Publication Date
JP2016534092A JP2016534092A (ja) 2016-11-04
JP2016534092A5 true JP2016534092A5 (cg-RX-API-DMAC10.html) 2017-04-27
JP6427789B2 JP6427789B2 (ja) 2018-11-28

Family

ID=54873835

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016529755A Active JP6427789B2 (ja) 2013-07-23 2014-04-17 Cl2aリンカーを有する抗体−sn−38免疫複合体

Country Status (5)

Country Link
EP (1) EP3024460B1 (cg-RX-API-DMAC10.html)
JP (1) JP6427789B2 (cg-RX-API-DMAC10.html)
CN (2) CN110075295A (cg-RX-API-DMAC10.html)
AU (1) AU2014293670B2 (cg-RX-API-DMAC10.html)
CA (1) CA2914438C (cg-RX-API-DMAC10.html)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7043425B2 (ja) * 2016-06-06 2022-03-29 ジェネンテック, インコーポレイテッド シルベストロール抗体-薬物コンジュゲート及び使用方法
CN109562172B (zh) * 2016-08-11 2022-08-16 免疫医疗公司 抗HLA-DR抗体药物缀合物IMMU-140(hL243-CL2A-SN-38)在HLA-DR阳性癌症中的功效
CN108066772B (zh) * 2016-11-14 2021-07-13 中国科学院上海药物研究所 靶向tacstd2的抗体与药物偶联体(adc)分子
EP3548088A4 (en) * 2016-12-01 2020-07-22 Immunomedics, Inc. THERAPY FOR METASTATIC UROTHELIAL CANCER WITH THE ANTIBODY-DRUG CONJUGATE, SACITUZUMAB GOVITÉCAN (IMMU-132)
US11311626B2 (en) * 2017-05-02 2022-04-26 National Cancer Center Japan Plasmin-cleavable anti-insoluble fibrin antibody-drug conjugate
CN119219654A (zh) * 2017-12-15 2024-12-31 四川科伦博泰生物医药股份有限公司 生物活性物偶联物及其制备方法和用途
CN111542324B (zh) * 2018-02-11 2023-09-12 四川科伦博泰生物医药股份有限公司 细胞毒性剂及其偶联物、其制备方法及用途
WO2019195770A1 (en) 2018-04-06 2019-10-10 Atyr Pharma, Inc. Compositions and methods comprising anti-nrp2 antibodies
CN112638415B (zh) * 2018-07-26 2024-07-02 大有华夏生物医药集团有限公司 用于成像的组合物和方法
US11713347B2 (en) * 2019-01-23 2023-08-01 Millennium Pharmaceuticals, Inc. CD38-binding proteins comprising de-immunized Shiga toxin A subunit effectors
AU2020358854B2 (en) 2019-10-03 2026-08-13 Atyr Pharma, Inc. Compositions and methods comprising anti-NRP2 antibodies
BR112022011632A2 (pt) * 2019-12-16 2022-10-04 Jiangsu Hengrui Medicine Co Conjugado análogo de anticorpo exatecano anti-cea e uso farmacêutico do mesmo
US20230101735A1 (en) 2020-01-22 2023-03-30 Jiangsu Hengrui Medicine Co., Ltd. Anti-trop-2 antidody-exatecan analog conjugate and medical use thereof
CN111499685A (zh) * 2020-03-30 2020-08-07 联宁(苏州)生物制药有限公司 具有马来酰亚胺连接头的抗体偶联药物中间体及其合成方法
CN113527497B (zh) * 2020-04-16 2022-06-10 上海洛启生物医药技术有限公司 抗Trop2纳米抗体及其应用
KR102349925B1 (ko) * 2020-07-16 2022-01-12 주식회사 피노바이오 Fl118 약물을 포함하는 화합물 및 이를 이용한 면역접합체
WO2022078279A1 (zh) * 2020-10-12 2022-04-21 昆山新蕴达生物科技有限公司 抗体-药物偶联物及其应用
JP7626491B2 (ja) * 2021-03-12 2025-02-04 国立研究開発法人科学技術振興機構 Sn-38誘導体、当該誘導体を含むナノ粒子、医薬及び当該ナノ粒子の製造方法
CN113480651B (zh) * 2021-07-19 2022-07-08 华东师范大学 一种靶向人cd133的纳米抗体及其制备方法和应用
CA3225598A1 (en) 2021-07-21 2023-01-26 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Pharmaceutical composition containing anti-trop2 antibody drug conjugate and its application
EP4509139A4 (en) * 2022-04-14 2026-04-01 Suzhou Ribo Life Science Co Ltd CONJUGATES AND COMPOSITION, AS WELL AS THEIR PREPARATION PROCESS AND USE
CN114917222B (zh) * 2022-04-29 2023-02-28 佛山病原微生物研究院 一种Ganetespib在制备用于抗腺病毒感染的药物中的用途
CN116139267A (zh) * 2023-01-28 2023-05-23 华中科技大学同济医学院附属同济医院 小鼠cd74单克隆抗体在制备治疗肿瘤药物中的应用
CN121652224A (zh) * 2024-09-11 2026-03-13 粤港澳大湾区精准医学研究院(广州) 多肽偶联化合物、所得多肽偶联药物及其用途
CN119775347B (zh) * 2024-12-31 2025-10-10 英科新创(苏州)生物科技有限公司 水溶性吖啶磺酰胺羧酸标记物、制备方法、其应用及试剂盒
CN119775344B (zh) * 2024-12-31 2025-08-26 英科新创(苏州)生物科技有限公司 水溶性吖啶磺酰胺衍生物、制备方法、其应用及试剂盒
CN121177511B (zh) * 2025-11-05 2026-05-08 赣南医科大学 Immu-132与gsk2606414联用在制备抗结直肠癌药物中的应用及相关药物
CN122103264A (zh) * 2026-04-30 2026-05-29 浙江科技大学 一种驼血血清多肽及其在制备促成骨细胞增殖和/或分化产品中的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0028361D0 (en) * 2000-11-21 2001-01-03 Glaxo Group Ltd Method of separating extra chromosomal dna from other cellular components
SE0104462D0 (sv) * 2001-12-29 2001-12-29 Carlbiotech Ltd As Peptide purifcation (Peptidrening)
US8420086B2 (en) * 2002-12-13 2013-04-16 Immunomedics, Inc. Camptothecin conjugates of anti-CD22 antibodies for treatment of B cell diseases
PL3912643T3 (pl) * 2009-02-13 2023-01-23 Immunomedics Inc. Immunokoniugaty z połączeniem rozszczepialnym wewnątrzkomórkowo
US9198972B2 (en) * 2010-01-28 2015-12-01 Alnylam Pharmaceuticals, Inc. Monomers and oligonucleotides comprising cycloaddition adduct(s)
CN107753954A (zh) * 2012-12-13 2018-03-06 免疫医疗公司 功效改进且毒性降低的抗体与sn‑38的免疫缀合物的剂量

Similar Documents

Publication Publication Date Title
JP2016520548A5 (cg-RX-API-DMAC10.html)
JP2012500286A5 (cg-RX-API-DMAC10.html)
JP2016513098A5 (cg-RX-API-DMAC10.html)
JP7305704B2 (ja) T細胞療法のための診断方法
US20200345854A1 (en) Bispecific antibody capable of being combined with immune cells to enhance tumor killing capability, and preparation method therefor and application thereof
CN107735090B (zh) 具有cl2a接头的抗体-sn-38免疫缀合物
JP2013503184A5 (cg-RX-API-DMAC10.html)
US10669338B2 (en) Anti-PD-1 checkpoint inhibitor antibodies that block binding of PD-L1 to PD-1
US10040848B2 (en) Chimeric and humanized anti-histone antibodies
FI3903829T3 (fi) Solunsisäisesti katkeavan sidoksen omaavia immunokonjugaatteja
US20240252537A1 (en) Precision molecular adaptor system for car-t immunotherapy
JP2014514345A5 (cg-RX-API-DMAC10.html)
TW202319057A (zh) 為t細胞療法而調理患者的方法
JP2018522833A (ja) キメラ抗原受容体(car)コンストラクト、及びcarコンストラクトを発現するt細胞(car−t)またはnk細胞(car−nk)による疾患治療
EP3286224A1 (en) Isolation, detection, diagnosis and/or characterization of circulating trop-2-positive cancer cells
US10206918B2 (en) Efficacy of anti-HLA-DR antiboddy drug conjugate IMMU-140 (hL243-CL2A-SN-38) in HLA-DR positive cancers
JP2016534092A (ja) Cl2aリンカーを有する抗体−sn−38免疫複合体
US20170216447A1 (en) Combination therapy with anti-hla-dr antibodies and kinase inhibitors in hematopoietic cancers
CN109562172B (zh) 抗HLA-DR抗体药物缀合物IMMU-140(hL243-CL2A-SN-38)在HLA-DR阳性癌症中的功效
Wang et al. Efficacy and safety of a novel CD19, CD22 dual-targeted fully human loop bi-CAR-T for the treatment of relapsed/refractory B cell non-Hodgkin lymphoma
WO2021022044A1 (en) Depletion regimes for engineered t-cell or nk-cell therapy
Suzuki et al. Advances and future perspectives in chimeric antigen receptor T-cell and bispecific antibody therapies for multiple myeloma
Huang et al. BCMA-CD19 Dual-Targeted CAR-T Cell Therapy for Relapsed or Refractory AL Amyloidosis
Byun et al. Chimeric antigen receptor-T cell therapy
CN119638851A (zh) 一种用于桥接造血干细胞移植的多靶点嵌合抗原受体及其应用